Articles tagged "Immunosuppression"

2020 American Transplant Congress
Development and Cell Surface Testing of a Novel Nanofiber Technology for Targeted Delivery of Therapeutic Regulatory T Cells
J. M. Mathew¹, S. Lee², Y. Sambandam¹, L. A. Fraser², T. D. Clemons², A. Kolberg², J. He¹, L. C. Palmer², M. T. McClendon², Z. J. Zhang¹, J. R. Leventhal¹, S. I. Stupp², L. Gallon¹
¹Surgery -Transplant, Northwestern University, Chicago, IL, ²Simpson Querrey Institute, Northwestern University, Chicago, IL
*Purpose: Regulatory CD4+CD25+FOXP3+ T cells (Tregs) have been shown to induce tolerance in transplantation models, and to be increased in their numbers in tolerant human…
2020 American Transplant Congress
2-Year Results of a Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients
J. Hagopian¹, S. January¹, N. Nesselhauf¹, K. Progar¹, T. Horwedel², R. Delos Santos³
¹Barnes-Jewish Hospital, Saint Louis, MO, ²Veloxis Pharmaceuticals, Cary, NC, ³Washington University, Saint Louis, MO
*Purpose: In December 2015, our center instituted a protocol change moving to de novo use of tacrolimus-XR (LCPT). The objective of this extension study is…
2020 American Transplant Congress
Prospective, Randomized Study of Conversion from Calcineurin Inhibitor (CNI)- to Belatacept (BELA)-Based Maintenance Immunosuppression in Renal Transplant Recipients
K. Budde¹, R. Prashar², H. Haller³, M. Rial⁴, N. Kamar⁵, A. Agarwal⁶, J. de Fijter⁷, L. Rostaing⁸, S. Berger⁹, A. Djamali¹⁰, N. Leca¹¹, L. Allamassey¹², S. Gao¹², M. Polinsky¹², F. Vincenti¹³
¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Henry Ford Hospital, Detroit, MI, ³The Hannover Medical School, Hannover, Germany, ⁴Instituto de Nefrologia, Nephrology SA, Buenos Aires, Argentina, ⁵University of Toulouse, Toulouse, France, ⁶UVA Health, Charlottesville, VA, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Université Grenoble Alpes, Saint-Martin-d'Hères, France, ⁹University Medical Centre Groningen, Groningen, Netherlands, ¹⁰University of Wisconsin, Madison, WI, ¹¹UW Medical Center, Seattle, WA, ¹²Bristol-Myers Squibb, Princeton, NJ, ¹³University of California, San Francisco, San Francisco, CA
*Purpose: CNIs are associated with adverse systemic and nephrotoxic effects that negatively impact long-term patient and graft survival. In a phase 2 study, switching renal…
2020 American Transplant Congress
The Impact of Purposeful Reductions in Immunosuppression on Clinical Outcomes in Kidney Transplantation
K. Foster, H. Perkins, N. Patel, C. Perez, N. Pilch, H. Meadows, F. Bartlett, V. Rao, M. Casey, M. Posadas Salas, K. Soliman, J. McGillicuddy, D. Taber
MUSC Health, Charleston, SC
*Purpose: Reductions to immunosuppressive therapy (IS) are often made due to infection or other IS intolerances, but little is known of impact of these reductions…
2020 American Transplant Congress
Assessing Immunosuppression with Immunological Testing and Surveillance Biopsies Late after Liver and Intestine Transplantation (LT, IT)
L. Remaley, R. Falik, K. Soltys, G. Bond, J. Winnier, P. Kachmar, C. Ashokkumar, A. Ganoza, A. Kepler, A. Khanna, J. Squires, P. McKiernan, J. Rudolph, F. Alissa, G. Mazariegos, R. Sindhi
Pediatric Transplant, Pittsburgh, PA
*Purpose: Assessing adequacy of immunosuppression is essential during late allograft surveillance after LT or IT.*Methods: To explain why allograft function tests can be normal despite…
2020 American Transplant Congress
Preventing Allograft Rejection by Circrna FSCN1 Mediated Tolerogenic Dendritic Cells
B. Wang, Q. Zhou, V. Veramkovich, A. Greasley, S. Li, X. Zheng
Pathology, University of Western Ontario-LHSC, London, ON, Canada
*Purpose: Induction of immune tolerance is a major challenge in heart transplants. There is no robust treatment with fewer side effects for preventing chronic rejection.…
2020 American Transplant Congress
Induction Immunosuppression with Thymoglobulin May Improve Graft Outcomes without Increasing a Risk for Infection in Patients Undergoing Liver Transplantation Alone
M. Henry¹, T. Kitajima², J. Konel¹, S. Yeddula², M. Rizzari², K. Collins², D. Moonka², A. Yoshida², M. Abouljoud², S. Nagai³
¹Wayne State University School of Medicine, Detroit, MI, ²Henry Ford Hospital, Detroit, MI, ³Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: Immunosuppression protocols for liver transplant (LT) vary between institutions and roles of induction immunosuppression in LT remain controversial. The aim of this study was…
2020 American Transplant Congress
Basiliximab vs Antithymocyte Globulin Induction with Early Steroid Withdrawal in Kidney Transplant Recipients: Early Rejection Outcomes
A. Szczepanik¹, C. Burrelli¹, A. Bixby¹, K. Yadav², K. Chavin²
¹Pharmacy, University Hospital Cleveland Medical Center, Cleveland, OH, ²Surgery, University Hospital Cleveland Medical Center, Cleveland, OH
*Purpose: Steroid withdrawal within the first month of kidney transplant (KT) remains controversial and has demonstrated a higher risk of acute rejection. The impact of…
2020 American Transplant Congress
Evaluation of Leukopenia and Neutropenia Incidence, Treatment, and Clinical Response in Kidney and Liver Transplant Recipients
H. Kutzler, T. Webb, R. Cecere, D. O'Sullivan, P. Sheiner
Hartford Hospital, Hartford, CT
*Purpose: The purpose is to evaluate incidence, recurrence, therapy modifications, and complications of leukopenia and neutropenia (LN) in kidney (KTR) and liver transplant (LTR) recipients.*Methods:…
2020 American Transplant Congress
Recruitment in the Pediatric Heart Transplant TEAMMATE Trial: Observed vs. Expected
K. P. Daly, L. A. Sleeper, L. J. Addonizio, J. C. Alejos, S. Auerbach, M. J. Bock, A. Butto, W. F. Carlo, C. Castleberry, W. J. Dreyer, B. Feingold, J. M. Lamour, E. L. Albers, S. A. Hollander, G. L. Klein, A. Lal, E. Pahl, D. Peng, A. R. Punnoose, J. W. Rossano, T. D. Ryan, J. Su, D. L. Sutcliffe, S. Zangwill, C. S. Almond
TEAMMATE Trial Investigators, Boston, MA
*Purpose: The TEAMMATE (Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients using the MATE Score) Trial is the first multicenter effort to address key scientific…